Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
| Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
| BAFFR&CD3 BsAb - 01 | PCC | Hematological Malignancy,AutoImmunity | Blood tumor,Autoimmune disease |
5e5 of anti-BAFFR CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human BAFFR Protein, His Tag (Cat. No. BAR-HP2H6) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Immobilized Human BAFF Protein, Fc Tag (Cat. No. BAF-H5261) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human BAFFR Protein, Llama IgG2b Fc Tag (Cat. No. BAR-H5258) with an affinity constant of 44.5 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Ianalumab | NOV-5; VAY-736 | Phase 3 Clinical | Morphosys Ag, Novartis Pharma Ag | Anemia, Hemolytic, Autoimmune; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Thrombocytopenia; Hepatitis, Autoimmune; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Purpura, Thrombocytopenic, Idiopathic; Lupus Erythematosus, Systemic; Multiple Sclerosis; Lupus Nephritis; Idiopathic Pulmonary Fibrosis; Arthritis, Rheumatoid; Sjogren's Syndrome; Hematologic Neoplasms; Lymphoma, B-Cell, Marginal Zone | Details |
| CD19-BAFF Targeted CAR T-cells Therapy(YaKe Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd, Zhejiang University | Lymphoma, B-Cell; Autoimmune Diseases | Details | |
| ESG-206 | ESG-206 | Phase 1 Clinical | Shanghai Escugen Biotechnology Co Ltd | Lymphoma, B-Cell; Neoplasms; Lymphoma | Details |
| AUR-200 | AUR-200; AUR200 | Phase 1 Clinical | Thunderbolt Pharma Inc | Autoimmune Diseases | Details |
| BAFFR-CAR T cell therapy (PeproMene Bio Inc) | PMB-CT01; PMB-101 | Phase 1 Clinical | PeproMene Bio Inc, City Of Hope National Medical Center | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Biphenotypic, Acute | Details |
| Ianalumab | NOV-5; VAY-736 | Phase 3 Clinical | Morphosys Ag, Novartis Pharma Ag | Anemia, Hemolytic, Autoimmune; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Thrombocytopenia; Hepatitis, Autoimmune; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Purpura, Thrombocytopenic, Idiopathic; Lupus Erythematosus, Systemic; Multiple Sclerosis; Lupus Nephritis; Idiopathic Pulmonary Fibrosis; Arthritis, Rheumatoid; Sjogren's Syndrome; Hematologic Neoplasms; Lymphoma, B-Cell, Marginal Zone | Details |
| CD19-BAFF Targeted CAR T-cells Therapy(YaKe Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd, Zhejiang University | Lymphoma, B-Cell; Autoimmune Diseases | Details | |
| ESG-206 | ESG-206 | Phase 1 Clinical | Shanghai Escugen Biotechnology Co Ltd | Lymphoma, B-Cell; Neoplasms; Lymphoma | Details |
| AUR-200 | AUR-200; AUR200 | Phase 1 Clinical | Thunderbolt Pharma Inc | Autoimmune Diseases | Details |
| BAFFR-CAR T cell therapy (PeproMene Bio Inc) | PMB-CT01; PMB-101 | Phase 1 Clinical | PeproMene Bio Inc, City Of Hope National Medical Center | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Biphenotypic, Acute | Details |
This web search service is supported by Google Inc.
A-Z
